Ratings by RBC Capital (Trung Huynh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/20/2026 | Merck | MRK | Downgrade | Sector Perform (Outperform) |
152.20 (150.33) |
-1.23% | Details | |
| 8/4/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Sector Perform (N/A) |
|
Details | ||
| 7/31/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Sector Perform (N/A) |
|
Details | ||
| 7/10/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2026 | Pfizer | PFE | Upgrade | Sector Perform (Underperform) |
25.62 (28.45) |
11.05% | Details | |
| 5/4/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2026 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 4/20/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 3/16/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2026 | Abbvie | ABBV | New Coverage | Outperform (N/A) |
229.48 (256.46) |
11.76% | Details | |
| 2/24/2026 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
1058.56 (1149.36) |
8.58% | Details | |
| 2/24/2026 | Pfizer | PFE | New Coverage | Underperform (N/A) |
27.06 (25.62) |
-5.32% | Details | |
| 2/24/2026 | Merck | MRK | New Coverage | Outperform (N/A) |
123.82 (152.20) |
22.92% | Details | |
| 2/24/2026 | Bristol-Myers Squibb Co. | BMY | New Coverage | Sector Perform (N/A) |
61.25 (66.82) |
9.09% | Details |
